Novartis stock

NVS stock price: $89.00 -1.24% At close on August 22nd, 2019

Updated on:
August 22nd, 2019

4

Novartis closed today at $89.00 and slightly fell a disappointing -1.24%.

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers.

Should I buy Novartis stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading plan that fits your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.

None of our preferred buy setups matches with Novartis stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Novartis stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At Stocks2.com, we gathered 7 ratings published for NVS stock in the last month.

The general sentiment of these ratings is bearish for NVS stock, with 5 negative ratings.
Is NVS a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-7-5JPMorgan Chase & Co.n/aSell
2019-7-23Kepler Capital MarketsBuyHold
2019-7-23Argusn/aBuy
2019-4-10Morgan StanleyEqual WeightUnderweight
2019-1-29JPMorgan Chase & Co.n/aSell
2019-1-2JPMorgan Chase & Co.NeutralUnderweight
2019-1-16JPMorgan Chase & Co.n/aSell

Novartis stock analysis

Daily outlook

Novartis ended today at $89.00 and slightly fell a disappointing -1.24%.

Shares of Novartis closed today at $89.00 and slightly fell a disappointing -1.24%. On April NVS price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. On July/18, NVS hit new all time highs, pushing higher previous ATH of $93.65 recorded on June. New ATHs are usual entry points for many trading setups as there aren't higher resistences.

NVS stock chart (daily)

Weekly outlook

Novartis ended this week at $89.00 and decreased an unpleasant -0.53%. This was the 5th red week in a row, sliding in full a -5.17%. By mid July NVS skyrocketed a super good 5.74% in just one week.

Observing the weekly chart, NVS marked an uptrend of rising tops and rising bottoms. Since its last top by mid July at $95.00, price slid and bounced up back from $86.74. Breaking down under $86.74 would cancel the current uptrend and it might test lower supports. Note that $95.00 might act as a resistance line. Not so far away is the last all-time high Novartis marked by mid July. Early October, SMA20w and SMA40w crossed up triggering a rise of 19.91%. Late April NVS price bounced up over the SMA of 20 weeks that acted as support stopping new slides.

NVS stock chart (weekly)

Novartis stock price history

Novartis stock went public on November 7th, 1996 with a price of $13.471. Since then, NVS stock surged a 560.70%, with a yearly average of 25.50%. If you had invested right after NVS's IPO a $1,000 in Novartis stock in 1996, it would worth $5,607.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Novartis stock historical price chart

NVS stock reached all-time highs on Jul 18th with a price of $95.00.

Novartis stock price target is $105.00

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we only found 1 price prediction for Novartis stock:
NVS stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-7-23ArgusRaises Targetn/a$105.00-
(in average)$0.00$105.000.0%

Financials and fundamental analysis

Earnings date and Earnings per Share

On January, Novartis failed to meet the forecasts of the analysts and reported an unpleasant EPS of $1.24 per share when experts were expecting $1.33.
NVS earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q2-n/a0.86n/a
2017-Q3-n/a0.94n/a
2017-Q4-n/a0.76n/a
2018-Q12018-04-191.251.282.4%
2018-Q22018-07-181.271.26-0.8%
2018-Q32018-10-181.311.310.0%
2018-Q42019-01-301.331.24-6.8%
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a
2019-Q3-n/an/an/a

Annual financial results

In 2018, Novartis annual sales jumped an excellent 6.05% to $53,166.00 million USD from $50,135.00 marked in 2017. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) escalated a 8.36% to 23.72%.

NVS annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY
2013$48,290 M-$8,520 M17.6%-
2014$53,634 M11.07%$10,210 M19.0%19.84%
2015$50,387 M-6.05%$17,783 M35.3%74.17%
2016$49,436 M-1.89%$6,712 M13.6%-62.26%
2017$50,135 M1.41%$7,703 M15.4%14.76%
2018$53,166 M6.05%$12,611 M23.7%63.72%

Quarterly financial results

Novartis reported $13,664.00 million in sales for 2018-Q4, a 4.14% improvement compared to previous quarter. Reported quarter income marked $1,195.00 million with a profit margin of 8.75%. Profit margin decreased a -3.62% compared to previous quarter when profit margin was 12.37%. When comparing revenues to same quarter last year, Novartis sales marked a good growth and inched a 3.80%.
NVS quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2
2017-Q2$12,050 M-$1,950 M16.2%-
2017-Q3$11,950 M-0.83%$2,000 M16.7%2.56%
2017-Q4$13,164 M10.16%$1,976 M15.0%-1.20%
2018-Q1$12,929 M-1.79%$2,025 M15.7%2.48%
2018-Q2$13,452 M4.05%$7,768 M57.7%283.60%
2018-Q3$13,121 M-2.46%$1,623 M12.4%-79.11%
2018-Q4$13,664 M4.14%$1,195 M8.7%-26.37%
2019-Q1$11,455 M-16.17%$1,766 M15.4%47.78%

Novartis ownership

When you are planning to invest in a stock, it's always worth to check its ownership structure.

Novartis shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.00% of all shares.

In case of Novartis stock, 11.69% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for NVS stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Novartis:

NVSABTBMYGSKJNJ
Market cap$203.8 B$149.4 B$77.9 B$101.3 B$349.9 B
Total shares2,290.0 M1,760.0 M1,630.0 M2,490.0 M2,660.0 M
Float shares2,150.0 M1,750.0 M1,630.0 M2,440.0 M2,630.0 M
  - Institutional holdings (%)11.7%76.5%75.0%11.0%69.2%
  - Insider holdings (%)0.0%0.7%0.1%0.0%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Novartis summary

Thursday, August 22nd, 2019
Open$89.25
Close$89.00
Day range$88.89 - $89.63
Previous close$90.12
Session gain-1.24%
Average true range$1.63
50d mov avg$91.07
100d mov avg$87.04
200d mov avg$82.37
Daily patternlt11a
Weekly pattern lb03a

Novartis performance

To better understand Novartis performance you must compare its gains with other related stocks in same sector or industry. For Novartis, the benchmark is made against , Bristol-Myers Squibb, GlaxoSmithKline, , Merck, Pfizer, and Teva Pharmaceutical Industries.
Stock3m6m12m
NVSNovartis1.69%12.96%22.44%
ABT10.71%12.39%30.60%
BMYBristol-Myers Squ...2.95%-4.63%-17.77%
GSKGlaxoSmithKline2.47%2.75%3.67%
JNJ-5.27%-2.41%-0.66%
MRKMerck7.80%9.07%29.36%
PFEPfizer-16.10%-17.35%-14.87%
SNY2.18%9.28%3.28%
TEVATeva Pharmaceutic...-31.46%-56.81%-67.64%

Novartis competitors

We picked a few stocks to conform a list of Novartis competitors to review if you are interested in investing in NVS:

Latest Novartis stock news